OMER News and Press, Omeros Corporation From 08/12/19

August 12, 2019 Palm Beach, FL – August 12, 2019 – Cellulite has been the bane of many women (and men too) for years, but the market is expected to rise significantly through 2026, industry reports project. One report said that the global cellulite treatment market...

Omeros Corporation (Nasdaq: OMER), today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the 2019 Wedbush PacGrow Healthcare Conference in New York next week. The presentation is scheduled for Wednesday, August 14, 2019 at 2:30 p.m. EDT. Th...

Omeros Corporation (OMER) Q2 2019 Earnings Conference Call August 8, 2019 16:30 ET Company Participants Jennifer Williams - Investor Relations Greg Demopulos - Chairman and Chief Executive Officer Mike Jacobsen - Chief Accounting Officer Conference Call Participants Steve B...

Omeros (NASDAQ: OMER ): Q2 GAAP EPS of -$0.29 beats by $0.15 . Revenue of $26.8M (+1476.5% Y/Y) beats by $1.47M . Press Release More news on: Omeros Corporation, Earnings news and commentary, Healthcare stocks news,

– Conference Call Today at 4:30 p.m. ET – Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications target...

Omeros Corporation (NASDAQ: OMER) today announced that the company will issue its second quarter 2019 financial results for the period ended June 30, 2019, on Thursday, August 8, 2019, after the market closes. Omeros management will host a conference call and webcast that day at 4:30 p.m. Eas...

Omeros Corporation (Nasdaq: OMER) and Lonza (SWX: LONN) today announced a long-term manufacturing agreement for commercial production of narsoplimab, Omeros’ lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), also referred to as OMS721...

-- Effective October 1, 2019, New Code Expected to Expand Reimbursement -- Omeros Corporation today announced that the Centers for Medicare and Medicaid Services (CMS) confirmed its preliminary decision to assign a permanent product-specific Healthcare Common Procedure Coding System ...

Investment Thesis Summary On October 1, 2018, shares of Omeros Corporation (NASDAQ: OMER ) dropped about 40% when the company announced positive phase 2 data for lead pipeline candidate narsoplimab . Investors were scared off by the fact that, following the initial 12-week course of treatm...

Immunic (NASDAQ: IMUX ) +17% . More news on: Immunic, Inc., Foresight Autonomous Holdings Ltd., Jaguar Health, Inc., Stocks on the move, Read more ...